Jpmorgan Chase & CO Arbutus Biopharma Corp Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 538,629 shares of ABUS stock, worth $2.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
538,629
Previous 896,258
39.9%
Holding current value
$2.31 Million
Previous $2.93 Million
35.87%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ABUS
# of Institutions
182Shares Held
118MCall Options Held
1MPut Options Held
478K-
Morgan Stanley New York, NY24.2MShares$103 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$57.1 Million14.31% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$49.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY10.4MShares$44.7 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$38.9 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $642M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...